scholarly journals Risk of Anastrozole-related Mood Disturbances and Dizziness among Breast Cancer Patients taking Anastrozole

2020 ◽  
Vol 1 (1) ◽  

Background: Anastrozole has been widely utilized in the management of endocrine sensitive post-menopausal breast cancer; however, there is high variability in the adverse reactions associated with its use. Anastrozole-associated mood disturbances and dizziness occur less frequently. However, they can still affect the quality of life of breast cancer patients. The aim of this study was to determine the clinical and demographic factors associated with Anastrozole's adverse events. Materials/Methods: This is a cross-sectional study of oestrogen receptor positive post-menopausal women (n = 97) with stages I to III breast cancer receiving Anastrozole (1mg daily). Multivariate analyses were performed to establish the factors associated with Anastrozole-induced mood disturbance and dizziness. Results: Approximately 20.6% and 13.4% of the subjects experienced mood disturbance and dizziness respectively. Patients who are on Anastrozole treatment for more than three years had higher odds of having mood disturbance (adjusted odds ratio 20.31, confidence interval 1.75 to 235.31, p = 0.016). No significant association was established between serum oestrogen levels and development of mood disturbance and dizziness. Conclusion: Our study confirmed that although mood disturbances and dizziness are not the most commonly reported adverse reactions, the duration of Anastrozole treatment may be a predictor of mood disturbance in these patients.

2021 ◽  
pp. 107815522110391
Author(s):  
Sujana H Chowdhury ◽  
Bilkis Banu ◽  
Nasrin Akter ◽  
Sarder M Hossain

Background Breast cancer survivor goes through a period of needs in their post-treatment daily life. Relatively few studies have been conducted to understand the unmet needs among breast cancer survivors in Bangladesh. Recognize and measure patterns and predictors of unmet needs of breast cancer patients was the aim of the study. Objective To identify and measure patterns and predictors of unmet needs of breast cancer patients in Bangladesh. Method A cross-sectional study among 138 breast cancer patients; conveniently selected from two public and two private cancer institutes. Face-to-face interview for data collection and medical record review for checklist was done. Unmet needs have been determined by the supportive care needs survey short form 34 scale. Logistic regression analyses were performed to identify the predictors of unmet needs. Results The study indicated the top 10 moderate-to-high needs; among which the top five needs were from the information need domain. Surprisingly, private cancer treatment centers were identified as a significant predictor for unmet needs. Patients from private cancer institutes reported more explanation needs as well as needs with their physical and daily living and sexuality. Furthermore, the type of treatment like patient receiving combine treatment therapy reported more need for help compared to the patient receiving chemotherapy alone. Moreover, housewives reported the low need for patient care and support systems as a result of their reluctant behavior towards their health. Conclusion Individual’s unmet need assessment should be a part of every treatment protocol of breast cancer for a better treatment outcome.


2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 320-320
Author(s):  
Kenza Drareni ◽  
Moustafa Bensafi ◽  
Helene Lusson ◽  
Damien Vansteene ◽  
Agnès Giboreau ◽  
...  

Abstract Objectives Given the influence of sensory signals on food intake regulation and the subsequent nutritional status, it is important to reduce the impact of commonly observed smell and taste alterations on the pleasure of eating during chemotherapy. This study aimed to examine the effect of various types of flavor enhancement on the appreciation of an appetizer by a group of patients undergoing chemotherapy. Methods Five eggplant appetizers with no seasoning (REF) or enhanced with either salt, lemon, garlic or cumin were developed. In this cross-sectional study, 36 healthy female subjects (age 58 ± 7 y) (control group) and 84 breast cancer patients (age 56 ± 11 y) treated with chemotherapy were recruited. A hierarchical cluster analysis based on patients' self-reported smell and taste abilities classified the patients in two groups: the ‘unaltered, (high sensory abilities) n = 49’ and the ‘altered, (poor sensory abilities), n = 35’ group. Participants tasted and assessed the appreciation of the reference appetizer on a visual analog scale and performed a randomized comparative liking task, by rating the appreciation for each flavor-enhanced appetizer relative to the REF (one-sample t-test). Results There was no significant difference in the appreciation of the REF appetizer between the three groups (P > 0.05). In the comparative liking task, the control group rated similarly the appreciation between the flavor-enhanced and the REF appetizers except for the cumin-enhanced appetizer, which was appreciated significantly more than the REF (P < 0.001). Patients in both ‘altered’ and ‘unaltered’ groups appreciated similarly the cumin appetizer (P > 0.05), more the salt and garlic-enhanced appetizers (P ≤ 0.001, P = 0.005, respectively) and significantly less the lemon-enhanced appetizer relative to the REF (P = 0.029), confirming a tendency for patients to reject acid-flavored foods. Conclusions The salt and garlic enhancements were appreciated by the patients independent of the stage of chemotherapy or the severity of smell and taste alterations. Flavor enhancement seems a good strategy to maintain the pleasure of eating in patients undergoing chemotherapy. Further research is still needed on the appreciation and intake of a complete meal (starter, main course, dessert). Funding Sources APICIL and ELIOR groups.


2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 22160-22160
Author(s):  
N. Raizada ◽  
H. S. Vadiraja ◽  
R. M. Raghavendra ◽  
B. S. Ajaikumar ◽  
R. S. Bilimagga ◽  
...  

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18132-e18132
Author(s):  
Elna Kuehnle ◽  
Wulf Siggelkow ◽  
Iris Schrader ◽  
Kristina Luebbe ◽  
Stefanie Noeding ◽  
...  

e18132 Background: In 2003 the German Cancer Society and the German Society for Breast Disease introduced a number of Quality Indicators (QIs) to improve standards of breast cancer care. Although QIs should be based on clinical evidence, evidence for important subpopulations (i.e. vulnerable patients) is often limited. In this prospective cross-sectional study we assessed conformity and non-conformity of guidelines and their impact on clinical outcome in a real-world setting. Methods: This prospective analysis included patients with primary breast cancer. Patients with stage IV and recurrent breast cancer were excluded. Data was collected from 2012-2016 in six certified breast care centers using a personal questionnaire and data from the patients' medical records. Guideline adherence to a set of 11 QIs was explored. Overall survival (OS) and disease free survival (DFS) were correlated with fulfillment of QIs and tumor characteristics. Results: Survival analysis was conducted in 2390 patients with a median follow-up of 16 months. 88 (4%) patients had a recurrent disease. 31 (1.3%) patients died of breast cancer. Tumor stage, grading, Her2- and hormone receptor status and Ki-67 correlated with DFS and OS. 1725/1907 patients (90.5%) received a guideline adherent treatment. The most prevalent reasons for non-conformity were old age (24.7%) and/or comorbidity (20.9%). Breast cancer specific DFS and OS were not significantly different between patients treated adherent or not adherent to the guidelines. In contrast, survival analysis of death other than breast cancer showed a significantly worse OS (p = 0.006) for patients not treated according to guideline recommendation. Conclusions: Conformity of clinical guidelines was observed in the majority of patients including healthy and vulnerable patients. These patients tended to have a longer breast cancer specific survival. Patients who were not considered suitable for guideline-adherent therapy died more often from other medical reasons rather than from breast cancer. In our study 10% of the patients had a limited life expectancy due to old age and co-morbidities with no assumed benefit from guideline adherence.


Sign in / Sign up

Export Citation Format

Share Document